Novartis | NVS - Créanciers Commerciaux





Créanciers Commerciaux Changement Date
AbbVie USD 3.59B 28.65B 2025-12
Amgen USD 19.52B 1.37B 2026-03
AstraZeneca USD 22.51B 2.78B 2026-03
Bausch Health Companies USD 593M 7M 2026-03
Biogen USD 358.5M 73.5M 2026-03
Bristol-Myers Squibb USD 4.23B 659M 2026-03
Canopy Growth CAD 34.82M 14.85M 2026-03
Corcept Therapeutics USD 33.31M 7.14M 2026-03
Drreddys Laboratories INR 22.36B 21.91B 2026-03
Eli Lilly USD 5.03B 350M 2026-03
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 1.05B 2026-03
Glaxosmithkline GBP 14.34B 6.39B 2026-03
J&J USD 10.46B 1.53B 2026-03
Merck USD 3.86B 541M 2026-03
Novartis USD 4.32B 134M 2026-03
Novartis USD 4.32B 134M 2026-03
Pacira USD 14.01M 1.14M 2026-03
Perrigo USD 434.8M 39.7M 2026-03
Pfizer USD 4.51B 734M 2026-03
Phibro Animal Health USD 129.64M 3.65M 2026-03
Prestige Brands USD 22.79M 20.15M 2026-03
Roche Holding CHF 5.78B 1.27B 2025-12
Sanofi EUR 22.71B 219M 2026-03
Sanofi EUR 22.71B 219M 2026-03
Supernus Pharmaceuticals USD 10.17M 97.63M 2026-03
Zoetis USD 507M 20M 2026-03